(Q28374935)

Valvular heart disease associated with fenfluramine-phentermine

PubMed

published in

Cardiovascular Pathology

0 references

volume

8

0 references

page(s)

245-53

0 references

issue

5

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021

Further cases of valvular heart disease associated with fenfluramine-phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021

Appetite Suppressants and Valvular Heart Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021

Asymptomatic mitral and aortic valve disease is seen in half of the patients taking 'phen-fen'.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021

An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021

Valvular heart disease associated with fenfluramine-phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021

Primary pulmonary hypertension and fenfluramine use

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021

Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021

Endocardial fibrosis associated with fenfluramine-phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021

The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021

Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021

Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021

Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021

The spectrum of severe rheumatic mitral valve disease in a developing country. Correlations among clinical presentation, surgical pathologic findings, and hemodynamic sequelae

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021

Surgical pathology of the mitral valve: a study of 712 cases spanning 21 years

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021

New observations on the etiology of aortic valve disease: a surgical pathologic study of 236 cases from 1990.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2899%2900019-8

7 January 2021